The chemotherapy tolerance of gemcitabine and cisplatin in old patients with advanced pancreatic cancer
10.3760/cma.j.issn.1674-1935.2009.04.013
- VernacularTitle:老年晚期胰腺癌患者对吉西他滨联合顺铂化疗耐受性分析
- Author:
Hongying LI
;
Fei WANG
;
Ni AN
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Aged;
Antineoplastic drug combinations;
Drug tolerance
- From:
Chinese Journal of Pancreatology
2009;9(4):256-258
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the tolerance of chemotherapy based on gemcitabine and cisplatin in elderly patients (> 70 years old) with advanced pancreatic cancer. Methods Retrospective analysis in 34 elderly patients with advanced pancreatic cancer between January 2004 and January 2009 was performed. Results 6 patients had partial remission (PR) and 16 patients had stable diaease (SD). The clinical benefit response (CBR) rate was 64.7%. 18 patients reduced their analgesics dose exceeding 50% , as well as pain intensity descended exceeding 35% , 22 patients had the weight increased more than 7% and had improved general well-being. The incidence rate of nausea and vomiting was 38. 2% (13/34) , 4 patients had worsened liver function and aggravated skin and sclera stained yellow. Incidence of Ⅲ- Ⅳ myelosuppressive was 34. 6% , and there were decrease in the number of white blood cell, hemoglobin, platelets to some extent, the rate of thrombocytopenia was 28. 3% (12/34) , blood routine normalized after using G-CSF. There was no occurrence of peripheral neurotoxicity or chemotherapy-related death. Conclusions Chemotherapy of gemcitabine in combination with cisplatin was tolerable for elderly patients with advanced pancreatic cancer who were in good condition of behavior.
